Welcome to chemicalbook!
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook > Product Catalogue >API >Inhibitors >LX-4211

LX-4211

LX-4211 Structure
  • ₹0
  • Product name: LX-4211
  • CAS: 1018899-04-1
  • MF: C21H25ClO5S
  • MW: 424.94
  • EINECS:
  • MDL Number:MFCD22493506
  • Synonyms:LX-4211;(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(Methylthio)tetrahydro-2H-pyran-3,4,5-triol;(5S)-Methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)Methyl]phenyl]-1-thio-beta-L-xylopyranoside;LX4211/LX-4211;LP 802034;LX4211 - L10525;LX-4211 (sotagliflozin);LX-4211, >=98%
Manufacturer Product number Product description Packaging Price Updated Buy

Properties

Boiling point :607.9±55.0 °C(Predicted)
Density :1.37±0.1 g/cm3(Predicted)
storage temp. :Store at -20°C
solubility :DMSO:84.0(Max Conc. mg/mL);197.67(Max Conc. mM)
Ethanol:17.0(Max Conc. mg/mL);40.01(Max Conc. mM) pka :12.87±0.70(Predicted)
form :Powder
color :White to off-white

Safety Information

Symbol(GHS): GHS hazard pictograms
Signal word: Warning
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
H351 Suspected of causing cancer Carcinogenicity Category 2 Warning P201, P202, P281, P308+P313, P405,P501
H373 May cause damage to organs through prolonged or repeated exposure Specific target organ toxicity, repeated exposure Category 2 Warning P260, P314, P501
Precautionary statements:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust/fume/gas/mist/vapours/spray.
P281 Use personal protective equipment as required.
P308+P313 IF exposed or concerned: Get medical advice/attention.
P314 Get medical advice/attention if you feel unwell.
P405 Store locked up.
P501 Dispose of contents/container to..…

Description

Inhibiting renal glucose reabsorption through the sodium-glucose cotransporter (SGLT) offers an insulin-independent alternative to controlling blood glucose concentrations in patients with type 2 diabetes. While the majority of glucose is reabsorbed from glomerular filtrate by SGLT2, which is predominantly expressed in the kidney S1 segment of the proximal tubule, SGLT1 reabsorbs glucose in the distal S3 segment of the renal proximal tubule as well as from the small intestine. Sotagliflozin is an orally available L-xyloside that potently inhibits both SGLT1 and SGLT2 (IC50s = 36 and 1.8 nM, respectively, for human isoforms in vitro). It improves glycemic control in nonobese diabetes prone mice with type 1 diabetes and in patients with type 2 diabetes in a randomized, placebo-controlled clinical trial. Sotagliflozin also increases serum glucagon-like peptide 1 and peptide YY levels by reducing SGLT1-mediated absorption of intestinal glucose.